Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium breve CECT7263
- Development stage
- Unknown
- Lead developer
- Biosearch Life
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
*Bifidobacterium breve* CECT7263 is a probiotic bacterial strain originally isolated from human breast milk. It is primarily developed for pediatric health applications, specifically for the treatment of infant colic and the prevention of neonatal morbidities such as necrotizing enterocolitis (NEC) in preterm infants. The strain functions by modulating the gut microbiota, enhancing the production of short-chain fatty acids (particularly acetate), and improving intestinal barrier integrity. In preclinical research, it has demonstrated potential in attenuating hypertension and endothelial dysfunction by reducing systemic endotoxemia and restoring the Th17/Treg immune balance. It is often utilized as a single-strain intervention or in combination with other probiotics like *Limosilactobacillus fermentum* CECT5716 in infant formulas and supplements.
- Other names
- B. breve CECT7263Bifidobacterium breve strain CECT7263
Beyond the preview
Go deeper on bifidobacterium breve CECT7263.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium breve CECT7263.